American Journal of Ophthalmology
Volume 148, Issue 6 , Pages 852-859.e2 , December 2009

Vision-Related Function After Scleral Lens Fitting in Ocular Complications of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

  • Bénédicte Tougeron-Brousseau

      Affiliations

    • Ophthalmology Department, Charles Nicolle Hospital, CHU de Rouen, Rouen, France
    • ,
  • Agnès Delcampe

      Affiliations

    • Ophthalmology Department, Charles Nicolle Hospital, CHU de Rouen, Rouen, France
    • Ophthalmology Department, Bichat Hospital, AP-HP, Paris, France
    • ,
  • Julie Gueudry

      Affiliations

    • Ophthalmology Department, Charles Nicolle Hospital, CHU de Rouen, Rouen, France
    • ,
  • Lisa Vera

      Affiliations

    • Ophthalmology Department, Charles Nicolle Hospital, CHU de Rouen, Rouen, France
    • ,
  • Serge Doan

      Affiliations

    • Ophthalmology Department, Bichat Hospital, AP-HP, Paris, France
    • ,
  • Thanh Hoang-Xuan

      Affiliations

    • Ophthalmology Department, Bichat Hospital, AP-HP, Paris, France
    • ,
  • Marc Muraine

      Affiliations

    • Ophthalmology Department, Charles Nicolle Hospital, CHU de Rouen, Rouen, France
    • Corresponding Author InformationInquiries to Marc Muraine, Department of Ophthalmology, Hôpital Charles Nicolle, 1 rue de Germont, 76031 Rouen, France

,Accepted 11 July 2009.

References 

  1. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129:92–96
  2. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331:1272–1285
  3. Revuz J, Penso D, Roujeau JC, et al. Toxic epidermal necrolysis (Clinical findings and prognosis factors in 87 patients). Arch Dermatol. 1987;123:1160–1165
  4. Power WJ, Ghoraishi M, Merayo-Lloves J, Neves RA, Foster CS. Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis disease spectrum. Ophthalmology. 1995;102:1669–1676
  5. Chang YS, Huang FC, Tseng SH, Hsu CK, Ho CL, Sheu HM. Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management. Cornea. 2007;26:123–129
  6. Correia O, Chosidow O, Saiag P, Bastuji-Garin S, Revuz J, Roujeau JC. Evolving pattern of drug-induced toxic epidermal necrolysis. Dermatology. 1993;186:32–37
  7. Khoo AK, Foo CL. Toxic epidermal necrolysis in a burns centre: a 6-year review. Burns. 1996;22:275–278
  8. Pushker N, Tandon R, Vajpayee RB. Stevens-Johnson syndrome in India – risk factors, ocular manifestations, and management. Ophthalmologica. 2000;214:285–288
  9. Oplatek A, Brown K, Sen S, Halerz M, Supple K, Gamelli RL. Long-term follow-up of patients treated for toxic epidermal necrolysis. J Burn Care Res. 2006;27:26–33
  10. Gueudry J, Roujeau JC, Binaghi M, Soubrane G, Muraine M. Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol. 2009;145:157–162
  11. Roujeau JC, Phlippoteau C, Koso M, et al. Sjogren-like syndrome after drug-induced toxic epidermal necrolysis. Lancet. 1985;1:609–611
  12. Yip LW, Thong BY, Lim J, et al. Ocular manifestations and complications of Stevens-Johnson syndrome and toxic epidermal necrolysis: an Asian series. Allergy. 2007;62:527–531
  13. Sotozono C, Ang LP, Koizumi N, et al. New grading system for the evaluation of chronic ocular manifestations in patients with Stevens-Johnson syndrome. Ophthalmology. 2007;114:1294–1302
  14. Nordlund ML, Holland EJ, Kersten RC. Ocular surface reconstruction in a patient with complete ankyloblepharon resulting from Stevens-Johnson syndrome. Arch Ophthalmol. 2004;122:934–935
  15. Haber J, Hopman W, Gomez M, Cartotto R. Late outcomes in adult survivors of toxic epidermal necrolysis after treatment in a burn center. J Burn Care Rehabil. 2005;26:33–41
  16. Romero-Rangel T, Stavrou P, Cotter J, Rosenthal P, Baltatzis S, Foster CS. Gas-permeable scleral contact lens therapy in ocular surface disease. Am J Ophthalmol. 2000;130:25–32
  17. Pullum KW, Buckley RJ. A study of 530 patients referred for rigid gas permeable scleral contact lens assessment. Cornea. 1997;16:612–622
  18. Pullum KW, Whiting MA, Buckley RJ. Scleral contact lenses: the expanding role. Cornea. 2005;24:269–277
  19. Rosenthal P, Cotter J. The Boston Scleral Lens in the management of severe ocular surface disease. Ophthalmol Clin North Am. 2003;16:89–93
  20. Rosenthal P, Cotter JM, Baum J. Treatment of persistent corneal epithelial defect with extended wear of a fluid-ventilated gas-permeable scleral contact lens. Am J Ophthalmol. 2000;130:33–41
  21. Jacobs DS. Update on scleral lenses. Curr Opin Ophthalmol. 2008;19:298–301
  22. Schulze-Bonsel K, Feltgen N, Burau H, Hansen L, Bach M. Visual acuities “hand motion” and “counting fingers” can be quantified with the Freiburg visual acuity test. Invest Ophthalmol Vis Sci. 2006;47:1236–1240
  23. Lange C, Feltgen N, Junker B, Schulze-Bonsel K, Bach M. Resolving the clinical acuity categories “hand motion” and “counting fingers” using the Freiburg visual acuity test (FrACT). Graefes Arch Clin Exp Ophthalmol. 2009;247:137–142
  24. Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol. 2000;118:615–621
  25. Binaghi M, Koso M, Roujeau JC, Coscas G. [Ocular complications of Lyell's syndrome: recent concepts apropos of 26 cases]. J Fr Ophtalmol. 1985;8:239–243
  26. Arstikaitis MJ. Ocular aftermath of Stevens-Johnson syndrome. Arch Ophthalmol. 1973;90:376–379
  27. Nordmann JP, Viala M, Sullivan K, Arnould B, Berdeaux G. Psychometric validation of the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) French version: in a population of patients treated for ocular hypertension and glaucoma. Pharmacoeconomics. 2004;22:197–206
  28. Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001;119:1050–1058
  29. Vitale S, Goodman LA, Reed GF, Smith JA. Comparison of the NEI-VFQ and OSDI questionnaires in patients with Sjogren's syndrome–related dry eye. Health Qual Life Outcomes. 2004;2:44
  30. Levinson RD, Monnet D, Yu F, Holland GN, Gutierrez P, Brezin AP. Longitudinal cohort study of patients with birdshot chorioretinopathy. V (Quality of life at baseline). Am J Ophthalmol. 2009;147:346–350
  31. Segal O, Barkana Y, Hourovitz D, et al. Scleral contact lenses may help where other modalities fail. Cornea. 2003;22:308–310
  32. Jacobs DS, Rosenthal P. Boston scleral lens prosthetic device for treatment of severe dry eye in chronic graft-versus-host disease. Cornea. 2007;26:1195–1199
  33. Takahide K, Parker PM, Wu M, et al. Use of fluid-ventilated, gas-permeable scleral lens for management of severe keratoconjunctivitis sicca secondary to chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2007;13:1016–1021
  34. Miskala PH, Bass EB, Bressler NM, et al. Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: quality-of-life findings: SST Report No. 12. Ophthalmology. 2004;111:1981–1992
  35. Miskala PH, Hawkins BS, Mangione CM, et al. Responsiveness of the National Eye Institute Visual Function Questionnaire to changes in visual acuity: findings in patients with subfoveal choroidal neovascularization—SST Report No. 1. Arch Ophthalmol. 2003;121:531–539
  36. Lindblad AS, Clemons TE. Responsiveness of the National Eye Institute Visual Function Questionnaire to progression to advanced age-related macular degeneration, vision loss, and lens opacity: AREDS Report No. 14. Arch Ophthalmol. 2005;123:1207–1214
  37. Chang TS, Bressler NM, Fine JT, Dolan CM, Ward J, Klesert TR. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol. 2007;125:1460–1469
  38. Magina S, Lisboa C, Leal V, Palmares J, Mesquita-Guimaraes J. Dermatological and ophthalmological sequels in toxic epidermal necrolysis. Dermatology. 2003;207:33–36
  39. Pullum K, Buckley R. Therapeutic and ocular surface indications for scleral contact lenses. Ocul Surf. 2007;5:40–48
  40. Gungor I, Schor K, Rosenthal P, Jacobs DS. The Boston Scleral Lens in the treatment of pediatric patients. J AAPOS. 2008;12:263–267
  41. Cotter JM, Rosenthal P. Scleral contact lenses. J Am Optom Assoc. 1998;69:33–40
  42. Laroche JM, Baechele F, Delcampe A, Drouin M, Ortega M, Hoang-Xuan T. [Bringing back scleral contact lenses]. J Fr Ophtalmol. 2004;27:877–882
  43. Margolis R, Thakrar V, Perez VL. Role of rigid gas-permeable scleral contact lenses in the management of advanced atopic keratoconjunctivitis. Cornea. 2007;26:1032–1034
  44. Williams ZR, Aquavella JV. Management of exposure keratopathy associated with severe craniofacial trauma. J Cataract Refract Surg. 2007;33:1647–1650
  45. Rosenthal P, Croteau A. Fluid-ventilated, gas-permeable scleral contact lens is an effective option for managing severe ocular surface disease and many corneal disorders that would otherwise require penetrating keratoplasty. Eye Contact Lens. 2005;31:130–134
  46. Schein OD, Rosenthal P, Ducharme C. A gas-permeable scleral contact lens for visual rehabilitation. Am J Ophthalmol. 1990;109:318–322
  47. Tan DT, Pullum KW, Buckley RJ. Medical applications of scleral contact lenses: 1 (A retrospective analysis of 343 cases). Cornea. 1995;14:121–129
  48. Di Blasi Z, Kleijnen J. Context effects: powerful therapies or methodological bias?. Eval Health Prof. 2003;26:166–179

 Supplemental Material available at AJO.com.

PII: S0002-9394(09)00502-9

doi: 10.1016/j.ajo.2009.07.006

American Journal of Ophthalmology
Volume 148, Issue 6 , Pages 852-859.e2 , December 2009

Article Tools

* Image Usage & Resolution